Leptin-activity blockers: Development and potential use in experimental biology and medicine1

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 11, 2013, Pages 873-882

  Gertler, Arieh ^a   Solomon, Gili ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antagonist; Anti autoimmune diseases; Blood pressure; Cancer; Inflammatory disease; Leptin; Metabolic syndrome; T2DM model; Uremic cachexia

Indexed keywords

LEPTIN; MONOCLONAL ANTIBODY; NANOBODY; NEUTRALIZING ANTIBODY;

ADIPOCYTE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BIOLOGY; BONE METABOLISM; CACHEXIA; CARCINOGENESIS; ELEVATED BLOOD PRESSURE; ENERGY METABOLISM; HEAVY CHAIN; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MEDICINE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ANTIBODIES, NEUTRALIZING; CAMELS; HUMANS; LEPTIN; OBESITY; PEPTIDES; RECEPTORS, LEPTIN; SPECIES SPECIFICITY;

EID: 84885457523     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2013-0012     Document Type: Review

References (65)

1. Attig, L., Solomon, G., Ferezou, J., Abdennebi-Najar, L., Taouis, M., Gertler, A., et al. 2008. Early postnatal leptin blockage leads to a long-term leptin resistance and susceptibility to diet-induced obesity in rats. Int. J. Obes. (Lond.), 32(7): 1153-1160. doi:10.1038/ijo.2008.39. PMID:18379577.
2. Ballinger, A., Kelly, P., Hallyburton, E., Besser, R., and Farthing, M. 1998. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin. Sci. (Lond.), 94(5): 479-483. PMID:9682669.
3. Beltrand, J., Sloboda, D.L., Connor, K.L., Truong, M., and Vickers, M.H. 2012. The effect of neonatal leptin antagonism in male rat offspring is dependent upon the interaction bewteen prior maternal nutrition status and post-weaning diet. J. Nutr. Metab. 2012. doi:10.1155/2012/296935. PMID:22548153.
4. Boulanger, M.J., Chow, D.C., Brevnova, E.E., and Garcia, K.C. 2003. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science, 300(5628): 2101-2104. doi:10.1126/science.1083901. PMID:12829785.
5. Callebaut, I., Labesse, G., Durand, P., Poupon, A., Canard, L., Chomilier, J., et al. 1997. Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives. Cell. Mol. Life Sci. 53(8): 621-645. doi:10.1007/s000180050082. PMID:9351466.
6. Carpenter, B., Hemsworth, G.R., Wu, Z., Maamra, M., Strasburger, C.J., Ross, R.J., et al. 2012. Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody. Structure, 20(3): 487-497. doi:10.1016/j.str.2012.01.019. PMID:22405007.
7. Cheung, W., Yu, P.X., Little, B.M., Cone, R.D., Marks, D.L., and Mak, R.H. 2005. Role of leptin and melanocortin signaling in uremia-associated cachexia. J. Clin. Invest. 115(6): 1659-1665. doi:10.1172/JCI22521. PMID:15931394.
8. Cheung, W., Ayalon-Soffer, M., and Mak, R.H. 2011. Peripheral administration of the leptin antagonist BL-5040 ameliorates cachexia and normalizes muscle function in mice with chronic kidney disease. J. Cachexia Sarcopenia Muscle, 2(3): 209-261. doi:10.1007/s13539-011-0045-3. PMID:22476871.
9. Chow, D., He, X., Snow, A.L., Rose-John, S., and Garcia, K.C. 2001 Structure of an extracellular gp130 cytokine receptor signaling complex. Science, 291(5511): 2150-2155. doi:10.1126/science.1058308. PMID:11251120.
10. De Rosa, V., Procaccini, C., La Cava, A., Chieffi, P., Nicoletti, G.F., Fontana, S., et al. 2006. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J. Clin. Invest. 116(2): 447-455. doi: 10.1172/JCI26523. PMID:16410832.
11. De Rosa, V., Procaccini, C., Cali, G., Pirozzi, G., Fontana, S., Zappacosta, S., et al. 2007. A key role of leptin in the control of regulatory T cell proliferation. Immunity, 26(2): 241-255. doi:10.1016/j.immuni.2007.01.011. PMID:17307705.
12. Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A.F., Beil, F.T., et al. 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell, 100(2): 197-207. doi:10.1016/S0092-8674(00)81558-5. PMID:10660043.
13. Elinav, E., Ali, M., Bruck, R., Brazowski, E., Phillips, A., Shapira, Y., et al. 2009a. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology, 49(1): 278-286. doi:10.1002/hep.22584. PMID:19065677.
14. Elinav, E., Niv-Spector, L., Katz, M., Price, T.O., Ali, M., Yacobovitz, M., et al. 2009b. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology, 150(7): 3083-3091. doi:10.1210/en. 2008-1706. PMID:19342450.
15. Fazeli, M., Zarkesh-Esfahani, H., Wu, Z., Maamra, M., Bidlingmaier, M., Pockley, A.G., et al. 2006. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J. Immunol. Methods, 312(1-2): 190-200. doi:10.1016/j.jim.2006. 03.011. PMID:16690078.
16. Ferla, R., Bonomi, M., Otvos, L., Jr., and Surmacz, E. 2011. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer, 11: 303. doi:10.1186/1471-2407-11-303. PMID: 21771332.
17. Fong, T.M., Huang, R.R., Tota, M.R., Mao, C., Smith, T., Varnerin, J., et al. 1998. Localization of leptin binding domain in the leptin receptor. Mol. Pharmacol. 53(2): 234-240. PMID:9463481.
18. Garonna, E., Botham, K.M., Birdsey, G.M., Randi, A.M., Gonzalez-Perez, R.R., and Wheeler-Jones, C.P. 2011. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One, 6(4): e18823. doi:10.1371/journal.pone.0018823. PMID:21533119.
19. Gonzalez, R.R., and Leavis, P.C. 2003. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine, 21(2): 185-195. doi:10.1385/ENDO:21:2:185. PMID: 12897384.
20. Gonzalez, R.R., Cherfils, S., Escobar, M., Yoo, J.H., Carino, C., Styer, A.K., et al. 2006. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem. 281(36): 26320-26328. doi:10.1074/jbc.M601991200. PMID:16825198.
21. Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., et al. 2012. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 16(1): 44-54. doi:10.1016/j.cmet.2012.05.012. PMID:22768838.
22. Karmiris, K., Koutroubakis, I.E., and Kouroumalis, E.A. 2005. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. Inflamm. Bowel Dis. 11(9): 847-855. doi:10.1097/01.mib.0000178915. 54264.8f. PMID:16116320.
23. Karmiris, K., Koutroubakis, I.E., Xidakis, C., Polychronaki, M., and Kouroumalis, E.A. 2007. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 19(9): 789-794. doi:10.1097/MEG.0b013e3282202bca. PMID:17700265.
24. Kontermann, R.E. 2012. Antibody-cytokine fusion proteins. Arch. Biochem. Biophys. 526(2): 194-205. doi:10.1016/j.abb.2012.03.001. PMID:22445675.
25. Levi, J., Gray, S.L., Speck, M., Huynh, F.K., Babich, S.L., Gibson, W.T., et al. 2011. Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology, 152(9): 3385-3395. doi:10.1210/en.2011-0185. PMID:21750049.
26. Majumdar, P., Chen, S., George, B., Sen, S., Karmazyn, M., and Chakrabarti, S. 2009. Leptin and endothelin-1 mediated increased extracellular matrix protein production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes Metab. Res. Rev. 25(5): 452-463. doi:10.1002/dmrr.964. PMID:19391127.
27. Mak, R.H., Cheung, W., Cone, R.D., and Marks, D.L. 2006. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int. 69(5): 794-797. doi:10.1038/sj.ki.5000182. PMID:16518340.
28. Moon, H.S., Matarese, G., Brennan, A.M., Chamberland, J.P., Liu, X., Fiorenza, C.G., et al. 2011. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes, 60(6): 1647-1656. doi:10.2337/db10-1791. PMID:21617185.
29. Muller-Newen, G. 2003. The cytokine receptor gp130: faithfully promiscuous. Sci. STKE, 2003(201): PE40. doi:10.1126/stke.2003.201.pe40. PMID:14506288.
30. Niv-Spector, L., Gonen-Berger, D., Gourdou, I., Biener, E., Gussakovsky, E.E., Benomar, Y., et al. 2005a. Identification of the hydrophobic strand in the A-B loop of leptin as major binding site III: implications for large-scale preparation of potent recombinant human and ovine leptin antagonists. Biochem. J. 391(Pt. 2): 221-230. PMID:15952938.
31. Niv-Spector, L., Raver, N., Friedman-Einat, M., Grosclaude, J., Gussakovsky, E.E., Livnah, O., et al. 2005b. Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor. Biochem. J. 390(Pt. 2): 475-484. PMID:15842201.
32. Niv-Spector, L., Shpilman, M., Boisclair, Y., and Gertler, A. 2012. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist. Protein Expr. Purif. 81(2): 186-192. doi:10.1016/j. pep.2011.10.003. PMID:22040607.
33. Otvos, L., Jr., and Surmacz, E. 2011. Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev. Anticancer Ther. 11(8): 1147-1150. doi:10.1586/era.11.109. PMID:21916566.
34. Otvos, L., Jr., Kovalszky, I., Riolfi, M., Ferla, R., Olah, J., Sztodola, A., et al. 2011. Efficacy of a leptin receptor antagonist peptide in a mouse model of triplenegative breast cancer. Eur. J. Cancer, 47(10): 1578-1584. doi:10.1016/j.ejca. 2011.01.018. PMID:21353530.
35. Otvos, L., Jr., Kovalszky, I., Scolaro, L., Sztodola, A., Olah, J., Cassone, M., et al. 2011. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Biopolymers, 96(2): 117-125. doi:10.1002/bip.21377. PMID: 20564005.
36. Otvos, L., Jr., Shao, W.H., Vanniasinghe, A.S., Amon, M.A., Holub, M.C., Kovalszky, I., et al. 2011. Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides, 32(8): 1567-1574. doi:10.1016/j.peptides.2011.06.015. PMID:21723351.
37. Otvos, L., Jr., Terrasi, M., Cascio, S., Cassone, M., Abbadessa, G., De Pascali, F., et al. 2008. Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta, 1783(10): 1745-1754. doi:10.1016/j.bbamcr.2008.05.007. PMID:18555805.
38. Peelman, F., Van Beneden, K., Zabeau, L., Iserentant, H., Ulrichts, P., Defeau, D., et al. 2004. Mapping of the leptin binding sites and design of a leptin antagonist. J. Biol. Chem. 279(39): 41038-41046. doi:10.1074/jbc.M404962200. PMID:15213225.
39. Procaccini, C., De Rosa, V., Galgani, M., Carbone, F., Cassano, S., Greco, D., et al. 2012. Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J. Immunol. 189(6): 2941-2953. doi:10.4049/jimmunol.1200935. PMID:22904304.
40. Purdham, D.M., Rajapurohitam, V., Zeidan, A., Huang, C., Gross, G.J., and Karmazyn, M. 2008. A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heart. Am. J. Physiol. Heart Circ. Physiol. 295(1): H441-H446. doi:10.1152/ajpheart.91537. 2007. PMID:18469142.
41. Ramos, M.P., Rueda, B.R., Leavis, P.C., and Gonzalez, R.R. 2005. Leptin serves as an upstream activator of an obligatory signaling cascade in the embryoimplantation process. Endocrinology, 146(2): 694-701. doi:10.1210/en.2004-1186. PMID:15539553.
42. Raver, N., Vardy, E., Livnah, O., Devos, R., and Gertler, A. 2002. Comparison of R128Q mutations in human, ovine, and chicken leptins. Gen. Comp. Endocrinol. 126(1): 52-58. doi:10.1006/gcen.2001.7766. PMID:11944966.
43. Salomon, G., Niv-Spector, L., Gussakovsky, E.E., and Gertler, A. 2006. Large-scale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists. Protein Expr. Purif. 47(1): 128-136. doi:10.1016/j.pep.2005.09.016. PMID:16289983.
44. Sandowski, Y., Raver, N., Gussakovsky, E.E., Shochat, S., Dym, O., Livnah, O., et al. 2002. Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain. J. Biol. Chem. 277(48): 46304-46309. doi:10.1074/jbc.M207556200. PMID:12226096.
45. Scarpace, P.J., and Zhang, Y. 2009. Leptin resistance: a prediposing factor for diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296(3): R493-R500. doi:10.1152/ajpregu.90669.2008. PMID:19091915.
46. Shpilman, M., Niv-Spector, L., Katz, M., Varol, C., Solomon, G., Ayalon-Soffer, M., et al. 2011. Development and characterization of high affinity leptins and leptin antagonists. J. Biol. Chem. 286(6): 4429-4442. doi:10.1074/jbc.M110. 196402. PMID:21119198.
47. Siegmund, B., Lehr, H.A., and Fantuzzi, G. 2002. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology, 122(7): 2011-2025. doi:10. 1053/gast.2002.33631. PMID:12055606.
48. Siegmund, B., Sennello, J.A., Jones-Carson, J., Gamboni-Robertson, F., Lehr, H.A., Batra, A., et al. 2004. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut, 53(7): 965-972. doi:10.1136/gut. 2003.027136. PMID:15194645.
49. -/- mice. Immunobiology. doi:10.1016/j.imbio. 2013.04.020. [Epub ahead of print].
50. Singh, U.P., Singh, N.P., Guan, H., Busbee, B., Price, R.L., Taub, D.D., Mishra, M.K., Fayad, R., Nagarkatti, M., and Nagarkatti, P.S. 2013b. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int. Rev. Immunol. doi:10.3109/08830185.2013.809071.
51. Sitaraman, S., Liu, X., Charrier, L., Gu, L.H., Ziegler, T.R., Gewirtz, A., et al. 2004. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J. 18(6): 696-698. doi:10.1096/fj.03-0422fje. PMID:14977884.
52. Solomon, G., Monsonego-Ornan, E., Chapnik, N., Smith, E., Froy, O., D'Alessio, D., et al. 2012. New fast and reversible leptin antagonist-induced mice model of metabolic syndrome and T2DM. Paper presented at the ECE/ICE 2012, Florence, Italy.
53. Styer, A.K., Sullivan, B.T., Puder, M., Arsenault, D., Petrozza, J.C., Serikawa, T., et al. 2008. Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology, 149(2): 506-514. doi:10.1210/en.2007-1225. PMID:17962343.
54. Tam, J., Cinar, R., Liu, J., Godlewski, G., Wesley, D., Jourdan, T., et al. 2012. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 16(2): 167-179. doi:10.1016/j.cmet.2012.07. 002. PMID:22841573.
55. Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., et al. 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell, 83(7): 1263-1271. doi:10.1016/0092-8674(95)90151-5. PMID:8548812.
56. Teta, D. 2012. Adipokines as uremic toxins. J. Ren. Nutr. 22(1): 81-85. doi:10.1053/j.jrn.2011.10.029. PMID:22200420.
57. Tumer, N., Erdos, B., Matheny, M., Cudykier, I., and Scarpace, P.J. 2007. Leptin antagonist reverses hypertension caused by leptin overexpression, but fails to normalize obesity-related hypertension. J. Hypertens. 25(12): 2471-2478. doi:10.1097/HJH.0b013e3282e9a9fd. PMID:17984669.
58. Verploegen, S.A., Plaetinck, G., Devos, R., Van der Heyden, J., and Guisez, Y. 1997. A human leptin mutant induces weight gain in normal mice. FEBS Lett. 405(2): 237-240. doi:10.1016/S0014-5793(97)00192-0. PMID:9089297.
59. Zabeau, L., Lavens, D., Peelman, F., Eyckerman, S., Vandekerckhove, J., and Tavernier, J. 2003. The ins and outs of leptin receptor activation. FEBS Lett. 546(1): 45-50. doi:10.1016/S0014-5793(03)00440-X. PMID:12829235.
60. Zabeau, L., Defeau, D., Van der Heyden, J., Iserentant, H., Vandekerckhove, J., and Tavernier, J. 2004. Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. Mol. Endocrinol. 18(1): 150-161. doi:10.1210/me.2003-0078. PMID: 14525952.
61. Zabeau, L., Verhee, A., Catteeuw, D., Faes, L., Seeuws, S., Decruy, T., et al. 2012. Selection of non-competitive leptin antagonists using a random nanobodybased approach. Biochem. J. 441(1): 425-434. doi:10.1042/BJ20110438. PMID: 21851341.
62. Zarkesh-Esfahani, H., Pockley, G., Metcalfe, R.A., Bidlingmaier, M., Wu, Z., Ajami, A., et al. 2001. High-dose leptin activates human leukocytes via receptor expression on monocytes. J. Immunol. 167(8): 4593-4599. PMID:11591788.
63. Zhang, F., Basinski, M.B., Beals, J.M., Briggs, S.L., Churgay, L.M., Clawson, D.K., et al. 1997. Crystal structure of the obese protein leptin-E100. Nature, 387(6629): 206-209. doi:10.1038/387206a0. PMID:9144295.
64. Zhang, J., Matheny, M.K., Tumer, N., Mitchell, M.K., and Scarpace, P.J. 2007. Leptin antagonist reveals that the normalization of caloric intake and the thermic effect of food after high-fat feeding are leptin dependent. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(2): R868-R874. doi:10.1152/ajpregu. 00213.2006. PMID:17023670.
65. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505): 425-432. doi:10.1038/372425a0. PMID:7984236.